These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25688104)

  • 1. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
    Gonzalez-Angulo AM; Krop I; Akcakanat A; Chen H; Liu S; Li Y; Culotta KS; Tarco E; Piha-Paul S; Moulder-Thompson S; Velez-Bravo V; Sahin AA; Doyle LA; Do KA; Winer EP; Mills GB; Kurzrock R; Meric-Bernstam F
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25688104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
    Chien AJ; Cockerill A; Fancourt C; Schmidt E; Moasser MM; Rugo HS; Melisko ME; Ko AH; Kelley RK; Korn WM; Esserman LJ; van't Veer L; Yau C; Wolf DM; Munster PN
    Breast Cancer Res Treat; 2016 Feb; 155(3):521-30. PubMed ID: 26875185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
    Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
    BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.
    Wisinski KB; Tevaarwerk AJ; Burkard ME; Rampurwala M; Eickhoff J; Bell MC; Kolesar JM; Flynn C; Liu G
    Clin Cancer Res; 2016 Jun; 22(11):2659-67. PubMed ID: 27026198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
    O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
    Pishvaian MJ; Slack R; Koh EY; Beumer JH; Hartley ML; Cotarla I; Deeken J; He AR; Hwang J; Malik S; Firozvi K; Liu M; Elston B; Strychor S; Egorin MJ; Marshall JL
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):843-53. PubMed ID: 23014737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Ma CX; Sanchez C; Gao F; Crowder R; Naughton M; Pluard T; Creekmore A; Guo Z; Hoog J; Lockhart AC; Doyle A; Erlichman C; Ellis MJ
    Clin Cancer Res; 2016 Jun; 22(11):2650-8. PubMed ID: 26783290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
    Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
    Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
    Delva R; Pienkowski T; Tubiana N; Vanhoefer U; Longerey B; Douville I
    Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
    Molife LR; Yan L; Vitfell-Rasmussen J; Zernhelt AM; Sullivan DM; Cassier PA; Chen E; Biondo A; Tetteh E; Siu LL; Patnaik A; Papadopoulos KP; de Bono JS; Tolcher AW; Minton S
    J Hematol Oncol; 2014 Jan; 7():1. PubMed ID: 24387695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
    Leong S; Cohen RB; Gustafson DL; Langer CJ; Camidge DR; Padavic K; Gore L; Smith M; Chow LQ; von Mehren M; O'Bryant C; Hariharan S; Diab S; Fox NL; Miceli R; Eckhardt SG
    J Clin Oncol; 2009 Sep; 27(26):4413-21. PubMed ID: 19652058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.
    Sessa C; Tosi D; Viganò L; Albanell J; Hess D; Maur M; Cresta S; Locatelli A; Angst R; Rojo F; Coceani N; Rivera VM; Berk L; Haluska F; Gianni L
    Ann Oncol; 2010 Jun; 21(6):1315-1322. PubMed ID: 19901013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.